IP Library Granted Patent US 11,419,841
Granted Patent B2
US 11,419,841 · App. 16/762,739 · Granted Aug 23, 2022

Uses of lipophenolic compounds

Inventors: Céline Crauste (Montpellier, FR); Joseph Vercauteren (Castelnau le Lez, FR); Francisco Veas (Mauguio, FR); Thierry Durand (Montpellier, FR); Nicolas Blondeau (Nice, FR)
A61K31/235
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,419,841
App. No.
16/762,739
Granted
Aug 23, 2022
Kind
B2
Abstract

The present invention relates to compound of formula (I): wherein R is O—R 3 or R 1 and R 2 are identical or different and are each independently H, (C 1 -C 6 )alkyl, —CO—(C 1 -C 21 )alkyl or —CO—(C 11 -C 21 )alkenyl group, provided that at least one of R 1 or R 2 is H or (C 1 -C 6 )alkyl, R 3 is a —CO—(C 11 -C 21 )alkyl or —CO—(C 11 -C 21 )alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Claims (5)

1. A method for the treatment of encephalitis comprising administering, to a person in need thereof, a compound of formula (IIb):

with R 3 selected from the group consisting of:

or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof.

2. The method of claim 1 , wherein the compound is administered for 1 to 4 days, and just before and/or during the acute phase response associated with factors inducing the increased vascular, lymphatic or mucosal permeability.

3. The method of claim 1 , wherein the compound of formula (IIb) is administered in association with at least one additional active compound selected from the group consisting of antibiotic, antiviral, antifungal, antiparasitic, anti-inflammatory active compound and mixtures thereof.

Assignments (2)
MERGER Recorded May 5, 2021
From: COMMUNAUTÉ D'UNIVERSITÉS ET ÉTABLISSEMENTS UNIVERSITÉ CÔTE D'AZUR
To: UNIVERSITÉ CÔTE D'AZUR
Reel/Frame 056143/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2021
From: CRAUSTE, CÉLINE; VERCAUTEREN, JOSEPH; VEAS, FRANCISCO; DURAND, THIERRY; BLONDEAU, NICOLAS
To: UNIVERSITE DE MONTPELLIER; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); ECOLE NATIONALE SUPERIEURE DE CHIMIE; INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD); UNIVERSITE D'AIX-MARSEILLE; COMMUNAUTE UNIVERSITES ET ETABLISSEMENTS UNIVERSITE COTE D AZUR
Reel/Frame 055839/0684 →
Priority Claims (1)
EP 17306560 · Nov 10, 2017 · regional
Continuity (1)
Related Publication 20200360334A1 · Nov 19, 2020